Adaptimmune

Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs 3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS 1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
SURPASS: evaluating the next-generation of SPEAR T-cell therapy 1:22
SURPASS: evaluating the next-generation of SPEAR T-cell therapy
Jo Brewer • 7 Apr 2021
Off-the-shelf iPSC therapies for solid tumors 4:23
Off-the-shelf iPSC therapies for solid tumors
Jo Brewer • 7 Apr 2021
The potential of iPSCs in cell therapy 1:28
The potential of iPSCs in cell therapy
Jo Brewer • 7 Apr 2021
Adaptimmune: SPEAR T-cells 6:02
Adaptimmune: SPEAR T-cells
Helen Tayton-Martin • 15 Oct 2020
T-cells: challenges in bringing to market 4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
The cell therapy landscape: disruptive technologies 3:12
The cell therapy landscape: disruptive technologies
Helen Tayton-Martin • 15 Oct 2020
The potential of RegenMed in the oncology space 1:41
The potential of RegenMed in the oncology space
Helen Tayton-Martin • 15 Oct 2020
The content of VJRegenMed is intended for healthcare professionals